» Articles » PMID: 36796530

Artificial Intelligence-assisted Selection and Efficacy Prediction of Antineoplastic Strategies for Precision Cancer Therapy

Overview
Specialty Oncology
Date 2023 Feb 16
PMID 36796530
Authors
Affiliations
Soon will be listed here.
Abstract

The rapid development of artificial intelligence (AI) technologies in the context of the vast amount of collectable data obtained from high-throughput sequencing has led to an unprecedented understanding of cancer and accelerated the advent of a new era of clinical oncology with a tone of precision treatment and personalized medicine. However, the gains achieved by a variety of AI models in clinical oncology practice are far from what one would expect, and in particular, there are still many uncertainties in the selection of clinical treatment options that pose significant challenges to the application of AI in clinical oncology. In this review, we summarize emerging approaches, relevant datasets and open-source software of AI and show how to integrate them to address problems from clinical oncology and cancer research. We focus on the principles and procedures for identifying different antitumor strategies with the assistance of AI, including targeted cancer therapy, conventional cancer therapy, and cancer immunotherapy. In addition, we also highlight the current challenges and directions of AI in clinical oncology translation. Overall, we hope this article will provide researchers and clinicians with a deeper understanding of the role and implications of AI in precision cancer therapy, and help AI move more quickly into accepted cancer guidelines.

Citing Articles

Invasion and metastasis in cancer: molecular insights and therapeutic targets.

Li Y, Liu F, Cai Q, Deng L, OuYang Q, Zhang X Signal Transduct Target Ther. 2025; 10(1):57.

PMID: 39979279 PMC: 11842613. DOI: 10.1038/s41392-025-02148-4.


Optimization of diagnosis and treatment of hematological diseases via artificial intelligence.

Wang S, Huang Z, Li J, Wu Y, Du J, Li T Front Med (Lausanne). 2024; 11:1487234.

PMID: 39574909 PMC: 11578717. DOI: 10.3389/fmed.2024.1487234.


Artificial intelligence, medications, pharmacogenomics, and ethics.

Haga S Pharmacogenomics. 2024; 25(14-15):611-622.

PMID: 39545629 PMC: 11703462. DOI: 10.1080/14622416.2024.2428587.


Artificial intelligence in oncology: ensuring safe and effective integration of language models in clinical practice.

Verlingue L, Boyer C, Olgiati L, Brutti Mairesse C, Morel D, Blay J Lancet Reg Health Eur. 2024; 46:101064.

PMID: 39290808 PMC: 11406067. DOI: 10.1016/j.lanepe.2024.101064.


Critical Appraisal and Future Challenges of Artificial Intelligence and Anticancer Drug Development.

Chamorey E, Gal J, Mograbi B, Milano G Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065667 PMC: 11279680. DOI: 10.3390/ph17070816.